Oxford Biomedica PLC PDMR Dealings (7254N)
September 26 2023 - 10:47AM
UK Regulatory
TIDMOXB
RNS Number : 7254N
Oxford Biomedica PLC
26 September 2023
PDMR Dealings
Oxford, UK - 26 September 2023: Oxford Biomedica plc ("Oxford
Biomedica" or " the Company") (LSE:OXB), a quality and
innovation-led viral vector CDMO, today announces that Leone
Patterson, Non-Executive Director, and Professor Dame Kay Davies,
Senior Independent Director, have both purchased ordinary shares in
the Company.
The ordinary shares purchased by Leone Patterson were acquired
pursuant to the Oxford Biomedica 2021 Remuneration Policy which was
approved at the 2021 Annual General Meeting, where an additional
fee of up to GBP50,000 per annum may be paid to any Non-Executive
Director recruited from or based in the United States to reflect
market levels of remuneration in the United States for
Non-Executive Directors, subject to their agreement that the after
tax amount of this additional fee will be used to acquire Oxford
Biomedica shares at market value, which must be retained for at
least 12 months from acquisition.
The following table sets out the number of shares purchased for
each Director and additional information.
Name of PDMR Number of Number of ordinary T otal number of
o rdinary shares now held ordinary shares
shares purchased held as a percentage
of the Company's
share capital
Leone Patterson 6, 598 1 2,447 0.013%
------------------ ------------------- ----------------------
K ay Davies 1 ,000 1 ,000 0 .001%
------------------ ------------------- ----------------------
The below notifications, made in accordance with the
requirements of the EU Market Abuse Regulation, give further
details of the number of ordinary shares purchased.
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Leone Patterson
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP2 .905 6 ,598
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6 ,598
* Aggregated total GBP1 9,167.19
----------------------------- -----------------------------------
f) Date of the transaction 2023-09-2 6; 13:30
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Kay Davies
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Senior Independent Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP2.91 1,000
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 1,000
GBP2,910
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-09-26; 12:37
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell
and gene therapy CDMO with a mission to enable its clients to
deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and near
Boston, MA, US. Learn more at www.oxb.com , www.oxbsolutions.com ,
and follow us on LinkedIn and YouTube .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFSSAEIRFIV
(END) Dow Jones Newswires
September 26, 2023 10:47 ET (14:47 GMT)
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From May 2024 to Jun 2024
Oxford Biomedica (AQSE:OXB.GB)
Historical Stock Chart
From Jun 2023 to Jun 2024